Importance of Time to Chemotherapy Initiation in Small Cell Lung Cancer
Gregory J Kubicek, Rachel Koehler, Matthew J Rossi, Christian Squillante, Alexander Hageboutros, Melvin Pratter, Stephen Akers and Polina Khrizman
Article Type: Original Article | First Published: April 20, 2019
Small cell lung cancer (SCLC) is an aggressive malignancy with a short median survival time. Because of the rapid growth rate there may be an advantage to emergently beginning chemotherapy as soon as SCLC diagnosis is made. All SCLC patients evaluated at Cooper University Hospital from January 2011 to September 2014 were reviewed. Multiple clinical factors were analyzed including timing between diagnosis and start of chemotherapy....
The Use of Carboranes in Cancer Drug Development
Emilia O Zargham, Christian A Mason and Mark W Lee Jr
Article Type: Review Article | First Published: April 18, 2019
Over the past decade, there has been a rising interest in the use of carboranes as a potential pharmacophoric moiety in the development of new drugs for the treatment of various types of cancer. The unique physical and chemical properties of carboranes make their use attractive in drug development. In several instances, the inclusion of carboranes into a drug structure has increased the agent's binding affinity, potency, or bioavailability. The purpose of this review is to highlight applications...
Does a New Information Structure about Cosmetic Outcome of Breast-Conserving Treatment Result in a Better Informed Patient? Outcome of a Comparative Case Study
ATPM Brands-Appeldoorn, MSc, AJG Maaskant-Braat, MD, PhD, VCG Tjan-Heijnen, MD, PhD and RMH Roumen, MD, PhD
Article Type: Original Article | First Published: April 17, 2019
A comparative case study compared data of two cross-sectional studies. The historical group (HG) was treated in 2013, the implementation group (IG) in 2016. The HG received a questionnaire, which resulted in implementation of the following items in our practice, expansion of the BCT brochure and photo book, incorporation of the Harvard and Numeric Rating scale. The IG received the same questionnaire, with the addition of nine more questions concerning specific implementation aspects....
Well Differentiated Neuroendocrine Uncommon Primary Breast Carcinoma: A Case Report
Angela Strazzanti, MD, Claudio Trovato, Angelo Caponnetto, Santi Gangi, Loredana R Villari, Pietro Gangemi and Francesco Basile
Article Type: Case Report | First Published: April 11, 2019
Neuroendocrine breast carcinomas (NEBC) are rarely malignant with a frequency of less than 0.1-0.3% of all breast tumors. The actual incidence of NEBC in BC (Breast Cancer) populations being still largely unknown due to the lack of a clear cut diagnostic criteria. In 2003, the World Health Organization (WHO) Classification of Tumors of the Breast and Female Genital Organs definitely established that the immunohistochemical expression of NE markers is the unique requirement for NEBC diagnosis....